According to the World Health Organisation (WHO), 500 000 cases of brucellosis are diagnosed in humans every year. Brucellosis is transmitted from animals to humans mainly by inhaling dust when handling products contaminated by brucella bacteria, or by consuming untreated milk from infected animals.
As the only international veterinary pharmaceutical group still actively present in the field of brucellosis control, Ceva is partnering prevention efforts in countries where the pathology is highly endemic. The group offers health authorities a comprehensive vaccination solution, combining the product itself and the technical expertise of one of the leaders in abortive diseases.
Ceva has developed a new type of vaccine, VECTORMUNE HVT-A1 (a vector vaccine), making the company one of the key players in the worldwide efforts to prevent the spread of avian flu.
It is forecast that by 2020 there will be a 50% deficit in global protein production. In this context Ceva is committed to finding new solutions to help improve the production of animal protein in around the world.